<p>ARS Pharmaceuticals（纳斯达克：SPRY - 获取免费报告）于周四公布了季度财报。该公司报告本季度每股收益为 0.52 美元，超出市场共识预期的（0.09 美元）0.61 美元，Zacks 报道。</p>
<p>获取 <strong>ARS Pharmaceuticals</strong> 的提醒：</p>
<h2>ARS Pharmaceuticals 价格表现</h2>
<p>周四，纳斯达克 SPRY 上涨 2.82 美元，达到 14.47 美元。该公司股票交易量为 4,254,858 股，而其平均交易量为 1,017,073 股。该股票市值为 14.1 亿美元，市盈率为-29.07，贝塔系数为 1.03。ARS Pharmaceuticals 的 12 个月低点为 7.55 美元，12 个月高点为 18.51 美元。该股票的 50 日简单移动平均为 11.98 美元，200 日简单移动平均为 13.03 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>SPRY 最近受到多份分析师报告的关注。威廉·布莱尔在 3 月 3 日的报告中重申了对 ARS Pharmaceuticals 股票的 “跑赢大盘” 评级。奥本海默在 2 月 10 日的报告中开始覆盖 ARS Pharmaceuticals 股票。他们对该股票设定了 “跑赢大盘” 评级和 40.00 美元的目标价。Leerink Partners 在 1 月 13 日的报告中将 ARS Pharmaceuticals 的目标价从 26.00 美元上调至 27.00 美元，并给予该公司 “跑赢大盘” 评级。斯科舍银行在 3 月 7 日的报告中开始覆盖 ARS Pharmaceuticals 股票。他们对该股票发布了 “行业跑赢大盘” 评级和 30.00 美元的目标价。最后，雷蒙德·詹姆斯在 1 月 14 日的研究报告中将 ARS Pharmaceuticals 的目标价从 26.00 美元上调至 28.00 美元，并给予该股票 “强烈买入” 评级。五位股票研究分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，ARS Pharmaceuticals 目前的共识评级为 “买入”，共识目标价为 31.00 美元。</p>
<p><strong>阅读我们关于 ARS Pharmaceuticals 的最新研究报告</strong></p>
<h2>ARS Pharmaceuticals 的内部交易</h2>
<p>在相关消息中，董事劳拉·肖弗于 3 月 6 日周四出售了 49,600 股该股票。股份以平均价格 11.21 美元出售，总交易额为 556,016.00 美元。交易后，该董事现在持有 210,346 股公司股票，价值约为 2,357,978.66 美元。此交易代表其持股减少了 19.08%。该交易已在提交给证券交易委员会的文件中披露，文件可通过此链接访问。在过去的九十天内，内部人士出售了价值 1,726,516 美元的 149,600 股公司股票。目前，内部人士持有该股票的 40.10%。</p>
<h2>关于 ARS Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>ARS Pharmaceuticals, Inc.是一家生物制药公司，开发严重过敏反应的治疗方案。该公司正在开发 neffy，一种无针和低剂量的鼻用肾上腺素喷雾剂，用于急救治疗 I 型过敏反应，包括过敏性休克。它为医疗专业人员、患者和护理人员提供服务。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 ARS Pharmaceuticals 更好</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>亚马逊股票的所有信号都表明买入——是时候加仓了吗？</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>五个理由说明 Five Below 的股价今年将上涨</li>
<li>三只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>博通：为什么这只芯片股票仍然是长期人工智能投资的首选</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 ARS Pharmaceuticals 吗？</h2>
<p>在你考虑 ARS Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 ARS Pharmaceuticals 并不在名单上。</p>
<p>虽然 ARS Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SPRY

<p>ARS Pharmaceuticals（纳斯达克代码：SPRY）报告每股收益为 0.52 美元，超出预期 0.61 美元。股价上涨 2.82 美元，达到 14.47 美元，市值为 14.1 亿美元。分析师维持 “买入” 的共识评级，目标价为 31.00 美元。最近的内部交易包括董事 Laura Shawver 出售 49,600 股。该公司专注于开发严重过敏反应的治疗方法，包括用于过敏性休克的无针肾上腺素鼻喷雾剂</p>

<p>ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.61, Zacks reports.</p>
<div class="lb-trans"><p>ARS Pharmaceuticals（纳斯达克：SPRY - 获取免费报告）于周四公布了季度财报。该公司报告本季度每股收益为 0.52 美元，超出市场共识预期的（0.09 美元）0.61 美元，Zacks 报道。</p>
</div><p>Get <strong>ARS Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ARS Pharmaceuticals</strong> 的提醒：</p>
</div><h2>ARS Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>ARS Pharmaceuticals 价格表现</h2>
</div><p>NASDAQ SPRY traded up $2.82 on Thursday, reaching $14.47. 4,254,858 shares of the company's stock traded hands, compared to its average volume of 1,017,073. The stock has a market cap of $1.41 billion, a PE ratio of -29.07 and a beta of 1.03. ARS Pharmaceuticals has a 12 month low of $7.55 and a 12 month high of $18.51. The stock has a 50-day simple moving average of $11.98 and a 200 day simple moving average of $13.03.</p>
<div class="lb-trans"><p>周四，纳斯达克 SPRY 上涨 2.82 美元，达到 14.47 美元。该公司股票交易量为 4,254,858 股，而其平均交易量为 1,017,073 股。该股票市值为 14.1 亿美元，市盈率为-29.07，贝塔系数为 1.03。ARS Pharmaceuticals 的 12 个月低点为 7.55 美元，12 个月高点为 18.51 美元。该股票的 50 日简单移动平均为 11.98 美元，200 日简单移动平均为 13.03 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>SPRY has been the subject of a number of recent analyst reports. William Blair reaffirmed an &#34;outperform&#34; rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an &#34;outperform&#34; rating and a $40.00 target price on the stock. Leerink Partners raised their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, January 13th. Scotiabank assumed coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a &#34;sector outperform&#34; rating and a $30.00 price target on the stock. Finally, Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a &#34;strong-buy&#34; rating in a research report on Tuesday, January 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of &#34;Buy&#34; and a consensus price target of $31.00.</p>
<div class="lb-trans"><p>SPRY 最近受到多份分析师报告的关注。威廉·布莱尔在 3 月 3 日的报告中重申了对 ARS Pharmaceuticals 股票的 “跑赢大盘” 评级。奥本海默在 2 月 10 日的报告中开始覆盖 ARS Pharmaceuticals 股票。他们对该股票设定了 “跑赢大盘” 评级和 40.00 美元的目标价。Leerink Partners 在 1 月 13 日的报告中将 ARS Pharmaceuticals 的目标价从 26.00 美元上调至 27.00 美元，并给予该公司 “跑赢大盘” 评级。斯科舍银行在 3 月 7 日的报告中开始覆盖 ARS Pharmaceuticals 股票。他们对该股票发布了 “行业跑赢大盘” 评级和 30.00 美元的目标价。最后，雷蒙德·詹姆斯在 1 月 14 日的研究报告中将 ARS Pharmaceuticals 的目标价从 26.00 美元上调至 28.00 美元，并给予该股票 “强烈买入” 评级。五位股票研究分析师对该股票给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat 的数据，ARS Pharmaceuticals 目前的共识评级为 “买入”，共识目标价为 31.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on ARS Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 ARS Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Insider Transactions at ARS Pharmaceuticals</h2>
<div class="lb-trans"><h2>ARS Pharmaceuticals 的内部交易</h2>
</div><p>In related news, Director Laura Shawver sold 49,600 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the transaction, the director now owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This trade represents a 19.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. In the last ninety days, insiders sold 149,600 shares of company stock worth $1,726,516. 40.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事劳拉·肖弗于 3 月 6 日周四出售了 49,600 股该股票。股份以平均价格 11.21 美元出售，总交易额为 556,016.00 美元。交易后，该董事现在持有 210,346 股公司股票，价值约为 2,357,978.66 美元。此交易代表其持股减少了 19.08%。该交易已在提交给证券交易委员会的文件中披露，文件可通过此链接访问。在过去的九十天内，内部人士出售了价值 1,726,516 美元的 149,600 股公司股票。目前，内部人士持有该股票的 40.10%。</p>
</div><h2>About ARS Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 ARS Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.</p>
<div class="lb-trans"><p>ARS Pharmaceuticals, Inc.是一家生物制药公司，开发严重过敏反应的治疗方案。该公司正在开发 neffy，一种无针和低剂量的鼻用肾上腺素喷雾剂，用于急救治疗 I 型过敏反应，包括过敏性休克。它为医疗专业人员、患者和护理人员提供服务。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than ARS Pharmaceuticals</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Everything About Amazon Stock Signals a Buy—Time to Load Up?</li>
<li>Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?</li>
<li>5 Reasons Five Below’s Stock Price Is Heading Higher This Year</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 ARS Pharmaceuticals 更好</li>
<li>资产配置：成功投资组合的关键。你在关注自己的投资组合吗？</li>
<li>亚马逊股票的所有信号都表明买入——是时候加仓了吗？</li>
<li>这些液化天然气股票准备迎来反弹吗？</li>
<li>五个理由说明 Five Below 的股价今年将上涨</li>
<li>三只沃伦·巴菲特在波动时期必须购买的股票</li>
<li>博通：为什么这只芯片股票仍然是长期人工智能投资的首选</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1BSWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SPRY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ARS Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 ARS Pharmaceuticals 吗？</h2>
</div><p>Before you consider ARS Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ARS Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ARS Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 ARS Pharmaceuticals 并不在名单上。</p>
</div><p>While ARS Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ARS Pharmaceuticals 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

ARS Pharmaceuticals（纳斯达克股票代码：SPRY）公布了收益结果，每股收益超出预期 0.61 美元